• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    2/23/22 8:15:30 AM ET
    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BFRA alert in real time by email

     

    Gainers

    • Revelation Biosciences (NASDAQ:REVB) stock increased by 29.9% to $2.0 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.4 million.
    • Biofrontera (NASDAQ:BFRA) shares rose 17.21% to $3.2. The market value of their outstanding shares is at $90.7 million.
    • Mainz Biomed (NASDAQ:MYNZ) stock moved upwards by 14.19% to $15.45. The company's market cap stands at $212.2 million.
    • Also check this: Tesla And 4 Other Stocks Sold By Insiders
    • Hims & Hers Health (NYSE:HIMS) shares rose 12.61% to $4.73. The company's market cap stands at $969.6 million. As per the press release, Q4 earnings came out yesterday.
    • NanoVibronix (NASDAQ:NAOV) shares increased by 11.18% to $0.83. The market value of their outstanding shares is at $23.1 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares rose 9.67% to $0.74. The market value of their outstanding shares is at $53.8 million.

     

    Losers

    • Kodiak Sciences (NASDAQ:KOD) shares decreased by 72.4% to $13.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $718.8 million.
    • Ocugen (NASDAQ:OCGN) shares declined by 19.15% to $3.42. The company's market cap stands at $681.2 million.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) shares declined by 10.56% to $10.0. The company's market cap stands at $367.6 million.
    • Plus Therapeutics (NASDAQ:PSTV) stock fell 9.61% to $0.91. The company's market cap stands at $19.3 million.
    • Diffusion Pharmaceuticals (NASDAQ:DFFN) stock declined by 8.71% to $0.21. The company's market cap stands at $21.9 million.
    • GreenLight Biosciences (NASDAQ:GRNA) shares fell 7.53% to $5.16. The market value of their outstanding shares is at $633.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BFRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFRA
    $DFFN
    $GRNA
    $HIMS

    CompanyDatePrice TargetRatingAnalyst
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$24.00Sell → Neutral
    Citigroup
    Hims & Hers Health Inc.
    $HIMS
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    Hims & Hers Health Inc.
    $HIMS
    3/9/2026$30.00Hold → Buy
    Needham
    Hims & Hers Health Inc.
    $HIMS
    2/24/2026Buy → Neutral
    BTIG Research
    PLUS THERAPEUTICS Inc.
    $PSTV
    2/3/2026$2.00Buy
    Lake Street
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    Hims & Hers Health Inc.
    $HIMS
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PAO Becklund Irene

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:59 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Policy Officer Autor Deborah M.

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Operating Officer Chi Michael

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    3/13/26 4:20:53 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Ocugen with a new price target

    Oppenheimer initiated coverage of Ocugen with a rating of Outperform and set a new price target of $10.00

    3/11/26 8:39:19 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Hims & Hers Health from Underperform to Neutral and set a new price target of $23.00

    3/10/26 8:37:14 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    SEC Filings

    View All

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/12/26 5:40:34 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PLUS THERAPEUTICS Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events

    8-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/12/26 4:35:23 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PLUS THERAPEUTICS Inc.

    10-K - PLUS THERAPEUTICS, INC. (0001095981) (Filer)

    3/12/26 4:29:32 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

    HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the fourth quarter and year ended December 31, 2025 and provides an overview of recent and upcoming business highlights. "Our team remains highly focused on achieving our 2026 targets," said Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer. "Specifically, our top priority goals are CNSide commercial scale-up and REYOBIQ pivotal trial readiness; we also are looking aggressively

    3/12/26 4:15:00 PM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposi

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Biotechnology: Pharmaceutical Preparations

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)

    4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/20/26 10:29:36 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Donahue Kevin Michael bought $258,827,700,000 worth of shares (643,850 units at $402,000.00) (SEC Form 4)

    4 - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/16/26 3:42:37 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Financials

    Live finance-specific insights

    View All

    Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

    HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery (CED) used in the administration of REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).   "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most

    2/25/26 7:30:00 AM ET
    $PSTV
    Medical/Dental Instruments
    Health Care

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events sec

    2/18/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BFRA
    $DFFN
    $GRNA
    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care